Femasys (FEMY) Competitors $0.92 -0.01 (-1.00%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.92 0.00 (0.00%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, FONR, MBOT, NTRB, APYX, GUTS, SRTS, VANI, TELA, and INOShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), Fonar (FONR), Microbot Medical (MBOT), Nutriband (NTRB), Apyx Medical (APYX), Fractyl Health (GUTS), Sensus Healthcare (SRTS), Vivani Medical (VANI), TELA Bio (TELA), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics Fonar Microbot Medical Nutriband Apyx Medical Fractyl Health Sensus Healthcare Vivani Medical TELA Bio Inovio Pharmaceuticals Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do analysts prefer FEMY or SLNO? Femasys currently has a consensus price target of $8.67, suggesting a potential upside of 842.03%. Soleno Therapeutics has a consensus price target of $107.10, suggesting a potential upside of 25.62%. Given Femasys' higher possible upside, equities analysts plainly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has stronger valuation and earnings, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M18.36-$18.82M-$0.91-1.01Soleno TherapeuticsN/AN/A-$175.85M-$4.62-18.45 Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. Soleno Therapeutics' return on equity of -77.52% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,242.06% -392.45% -137.15% Soleno Therapeutics N/A -77.52%-63.44% Which has more volatility and risk, FEMY or SLNO? Femasys has a beta of -2.56, suggesting that its stock price is 356% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.63, suggesting that its stock price is 363% less volatile than the S&P 500. Do insiders and institutionals believe in FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to FEMY or SLNO? In the previous week, Soleno Therapeutics had 6 more articles in the media than Femasys. MarketBeat recorded 7 mentions for Soleno Therapeutics and 1 mentions for Femasys. Femasys' average media sentiment score of 0.92 beat Soleno Therapeutics' score of 0.81 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFemasys and Soleno Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.23M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-1.0120.8026.9720.11Price / Sales18.36286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book9.207.487.985.56Net Income-$18.82M-$55.04M$3.16B$248.40M7 Day Performance-3.14%2.44%2.36%4.67%1 Month Performance15.00%1.90%2.15%6.64%1 Year Performance-16.36%4.35%33.78%21.31% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys3.7143 of 5 stars$0.92-1.0%$8.67+842.0%-19.3%$30.23M$1.63M-1.0130SLNOSoleno Therapeutics4.7672 of 5 stars$83.78+0.6%$107.10+27.8%+101.0%$4.20BN/A-18.1330FONRFonar1.25 of 5 stars$14.96+0.5%N/A-2.9%$92.31M$102.88M11.97480MBOTMicrobot Medical2.1974 of 5 stars$2.52+0.8%$9.00+257.1%+129.6%$90.94MN/A-3.8820Options VolumeNTRBNutriband3.2169 of 5 stars$7.87-1.4%$13.00+65.2%+37.3%$89.01M$2.14M-8.7410Gap DownAPYXApyx Medical1.681 of 5 stars$2.25+4.2%N/A+76.9%$81.64M$48.10M-4.09270GUTSFractyl Health2.0172 of 5 stars$1.62-1.2%$11.00+579.0%-65.3%$80.32M$90K-0.88102SRTSSensus Healthcare1.492 of 5 stars$4.74-2.5%$11.67+146.1%-18.7%$79.92M$39.49M47.4040VANIVivani Medical3.3574 of 5 stars$1.29-2.3%$4.00+210.1%+0.8%$78.20MN/A-3.0020TELATELA Bio2.9408 of 5 stars$1.94-1.5%$7.25+273.7%-54.7%$77.92M$69.30M-1.38120News CoverageINOInovio Pharmaceuticals3.7383 of 5 stars$2.04-3.3%$9.75+377.9%-84.6%$77.38M$220K-0.64320Gap Up Related Companies and Tools Related Companies Soleno Therapeutics Alternatives Fonar Alternatives Microbot Medical Alternatives Nutriband Alternatives Apyx Medical Alternatives Fractyl Health Alternatives Sensus Healthcare Alternatives Vivani Medical Alternatives TELA Bio Alternatives Inovio Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
